We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for lanadelumab (Takeda Pharmaceuticals Australia Pty Ltd)
Active ingredients
lanadelumab
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Solution for injection
Indication
Lanadelumab is indicated for the routine prevention of angioedema attacks and control of symptoms of HAE in paediatric patients 2 to <12 years
Therapeutic area
Immunology